KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Construction in Progress (2009 - 2022)

Amgen's quarterly Construction in Progress came in at $1.2 billion in Q4 2022, up 22.9% year-on-year from $987.0 million in Q4 2021, and up 22.9% quarter-over-quarter from $987.0 million in Q4 2021.

Amgen has reported Construction in Progress for 14 years, with the latest figure at $1.2 billion in Q4 2022.

  • For the quarter ending Q4 2022, Construction in Progress rose 22.9% year-over-year to $1.2 billion; the trailing twelve-month figure through Dec 2022 stood at $1.2 billion (up 22.9% YoY), and the FY2022 full-year result was $1.2 billion, up 22.9% from the prior year.
  • Construction in Progress for Q4 2022 stood at $1.2 billion, up from $987.0 million in the prior quarter.
  • The five-year high for Construction in Progress was $1.2 billion in Q4 2022, with the low at $907.0 million in Q4 2019.
  • Average Construction in Progress over 5 years is $995.0 million, with a median of $953.0 million recorded in 2018.
  • Year-over-year, Construction in Progress dropped 4.83% in 2019 and advanced 22.9% in 2022.
  • Tracing AMGN's Construction in Progress over 5 years: stood at $953.0 million in 2018, then dropped by 4.83% to $907.0 million in 2019, then climbed by 0.88% to $915.0 million in 2020, then rose by 7.87% to $987.0 million in 2021, then increased by 22.9% to $1.2 billion in 2022.
  • The last three Construction in Progress figures came in at $1.2 billion (Q4 2022), $987.0 million (Q4 2021), and $915.0 million (Q4 2020), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 1.54 Bn
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 1.21 Bn
Dec 31, 2021 987.00 Mn
Dec 31, 2020 915.00 Mn
Dec 31, 2019 907.00 Mn
Dec 31, 2018 953.00 Mn
Dec 31, 2017 834.00 Mn
Dec 31, 2016 745.00 Mn
Dec 31, 2015 746.00 Mn
Dec 31, 2014 1.18 Bn
Dec 31, 2013 1.12 Bn
Dec 31, 2012 1.07 Bn
Dec 31, 2011 744.00 Mn
Dec 31, 2010 631.00 Mn
Dec 31, 2009 910.00 Mn